by Steven Grossman | Nov 11, 2025 | Uncategorized
This week’s questions:Any initial thoughts on CDER Director George Tidmarsh’s response to being accused of abusing his office?Your column on national uniformity and federal preemption (here) was critical of both industry and consumer advocates who are involved in the...
by Steven Grossman | Nov 3, 2025 | Uncategorized
This week’s questions:What do you think about this past week’s stories on increased lobbying by pharma (and others) this year? Why was your analysis (here) of the nine vouchers awarded under the National Priority Review Voucher Initiative more positive than most? Q:...
by Steven Grossman | Oct 27, 2025 | Uncategorized
This week’s questions:It appears that no progress has been made to end the federal government shutdown. What happens next? There have been recent headlines that FDA’s FY 26 funding might be appropriated, separate from resolution of the shutdown. Is this true and...
by Steven Grossman | Oct 13, 2025 | Uncategorized
This week’s questions:How long is the shutdown likely to continue?Did Commissioner Makary offer companies accelerated review if they make the pricing concessions requested by the Administration?Where does the farm community fit into the MAHA agenda?——Q: How long...
